Common use of INITIATION OF TREATMENT Clause in Contracts

INITIATION OF TREATMENT. It is the responsibility of the ordering physician to ensure that the patient is fully informed about all available treatment alternatives, along with the risks and potential benefits associated with each alternativevii. XXXXXX has published a guide entitled Decisions in Recovery: Treatment for Opioid Use Disorder Handbookviii that may be of assistance to patients in making treatment choices, but such materials are intended to supplement rather than replace the discussion between physician and patient. Out of respect for the patient’s autonomy, counseling must be given in a non-directive fashion, occur face-to-face and provide an opportunity for the patient to ask questions prior to initiation of treatment. Prior to initiation of treatment with extended-release injectable naltrexone, the physician must: 1. Inform the patient of all options for medical treatment of opioid use disorder, including: a. methadone and buprenorphine for long-term maintenance; b. medication-assisted detoxification; and c. post-detoxification control of craving and other symptoms. 2. Ensure that the patient is an appropriate candidate for the use of the medication, in accordance with the selection criteria above, national guidelines and best practices; 3. Inform the patient of all risks associated with use of the medication as outlined in the FDA prescribing information, including: a. Vulnerability to opioid overdose i. following discontinuation of the medication ii. during attempts to overcome the medication’s blockade effect b. Precipitation of opioid withdrawal c. Injection site reactions d. Hepatotoxicity e. Depression & Suicidality f. Potential issues with acute pain management g. Eosinophilic pneumonia

INITIATION OF TREATMENT. It is the responsibility of the ordering physician to ensure that the patient is fully informed about all available treatment alternatives, along with the risks and potential benefits associated with each alternativeviialternative7. XXXXXX has published a guide entitled Decisions in Recovery: Treatment for Opioid Use Disorder Handbookviii Handbook8 that may be of assistance to patients in making treatment choices, but such materials are intended to supplement rather than replace the discussion between physician and patient. Out of respect for the patient’s autonomy, counseling must be given in a non-directive fashion, occur face-to-face and provide an opportunity for the patient to ask questions prior to initiation of treatment. Prior to initiation of treatment with extended-release injectable naltrexone, the physician must: 1. Inform the patient of all options for medical treatment of opioid use disorder, including: a. methadone and buprenorphine for long-term maintenance; b. medication-assisted detoxification; and c. post-detoxification control of craving and other symptoms. 2. Ensure that the patient is an appropriate candidate for the use of the medication, in accordance with the selection criteria above, national guidelines and best practices; 3. Inform the patient of all risks associated with use of the medication as outlined in the FDA prescribing information, including: a. Vulnerability to opioid overdose i. following discontinuation of the medication ii. during attempts to overcome the medication’s blockade effect b. Precipitation of opioid withdrawal c. Injection site reactions d. Hepatotoxicity e. Depression & Suicidality f. Potential issues with acute pain management g. Eosinophilic pneumonia

INITIATION OF TREATMENT. It is the responsibility of the ordering physician to ensure that the patient is fully informed about all available treatment alternatives, along with the risks and potential benefits associated with each alternativeviialternativeviii. XXXXXX has published a guide entitled Decisions in Recovery: Treatment for Opioid Use Disorder Handbookviii Handbookix that may be of assistance to patients in making treatment choices, but such materials are intended to supplement rather than replace the discussion between physician and patient. Out of respect for the patient’s autonomy, counseling must be given in a non-directive fashion, occur face-to-face and provide an opportunity for the patient to ask questions prior to initiation of treatment. Prior to initiation of treatment with extended-release injectable naltrexone, the physician must: 1. Inform the patient of all options for medical treatment of opioid use disorder, including: a. methadone and buprenorphine for long-term maintenance; b. medication-assisted detoxification; and c. post-detoxification control of craving and other symptoms. 2. Ensure that the patient is an appropriate candidate for the use of the medication, in accordance with the selection criteria above, national guidelines and best practices; 3. Inform the patient of all risks associated with use of the medication as outlined in the FDA prescribing information, including: a. Vulnerability to opioid overdose i. following discontinuation of the medication ii. during attempts to overcome the medication’s blockade effect b. Precipitation of opioid withdrawal c. Injection site reactions d. Hepatotoxicity e. Depression & Suicidality f. Potential issues with acute pain management g. Eosinophilic pneumonia